- Numinus recently became the first Canadian public company to complete a legal harvest of Psilocybe mushrooms.
- The company plans to significantly expand its research facility and its revenues are growing fast thanks to the acquisition of clinics that use psychedelic therapy treatments.
- Numinus is well-funded, which removes stock dilution risk in the near future.
- I think that the company’s valuation should be close to the ones of COMPASS Pathways and MindMed, which are among the leaders in the psychedelic therapy solutions space.
For further details see:
Hopes Are High For Numinus Wellness